Author name: Tejaswini Kaushal

Tejaswini is a SpicyIP Analyst and a B.A. LL.B. (Hons.) student at Dr. Ram Manohar Lohiya National Law University, Lucknow. She has a keen interest in Intellectual Property Law, Technology Law, and Corporate Law.

https://assets.medpagetoday.net/media/devqa/images/80xxx/80938.jpg

Novartis’s Heartache over Entresto: An Analysis of the Controller’s Patent Revocation Decision

/ By / Patent

[The post is co-authored with Vikram Raj Nanda. A big thanks to Swaraj and Praharsh for their inputs.] In a detailed 262-page order (pdf) dated 12th September, 2025, Dr Usha Rao, the Deputy Controller of Patents and Designs, annulled Novartis’ patent over its cardiac drug ‘Vymada’ (marketed internationally as ‘Entresto’). The Controller had cumulatively dealt with several post-grant oppositions that had been filed by the Indian Pharmaceutical Alliance, along with two firms: IPCA (Indian Pharmaceutical Combine Association) Laboratories and MicroLabs.  […]

Novartis’s Heartache over Entresto: An Analysis of the Controller’s Patent Revocation Decision Read More »

https://imgflip.com/i/a4y3lp

Justice with Velvet Gloves? A Look at the DHC’s Decision in the iPhone Counterfeit Case

/ By / Trademark

A division bench (DB) of the Delhi High Court (DHC), comprising Justices Prathiba M. Singh and Shail Jain, recently voiced serious concern over the import of counterfeit iPhones in M/s ECG Easy Connect Logistics Pvt. Ltd v Commissioner of Customs, CUSAA 35/2024 (pdf). The DB highlighted the dual harm caused by such imports: erosion of brand equity and adverse consumer welfare impacts, particularly as old, used, or counterfeit products may be misrepresented as new. This deceptive practice, according to the

Justice with Velvet Gloves? A Look at the DHC’s Decision in the iPhone Counterfeit Case Read More »

https://i.imgflip.com/a4645r.jpg

[SpicyIP Tidbit] A Heavy Dose of Litigation: Novo Nordisk sees Litigation from Natco over Semaglutide

/ By / Drug Regulation, Patent

Novo Nordisk’s blockbuster weight-loss drug Wegovy (semaglutide) continues to trigger a complex litigation landscape in India. The Danish innovator already has two civil suits pending against Dr. Reddy’s Laboratories (DRL) and OneSource Specialty Pharma Ltd (OSSPL). The first, C.O.(COMM.IPD-PAT) 9/2025, seeks revocation of a patent and has so far seen only four hearings with routine interim orders. The second, CS(COMM) 565/2025, was instituted in anticipation of Novo’s Indian launch and is more high-stakes: on 29 May 2025, the Single Bench

[SpicyIP Tidbit] A Heavy Dose of Litigation: Novo Nordisk sees Litigation from Natco over Semaglutide Read More »

https://i.imgflip.com/a35rdu.jpg

Gauging the ‘Weight’ of the Matter: Here’s Your Latest Patent and Litigation Update on Semaglutide

/ By / Patent

Still on the Scales: The Ongoing Patent Battle for Semaglutide Back in May 2025, the order (pdf) by the Delhi High Court (DHC), the Single Bench (SB) comprising Justice Amit Bansal, granted Novo Nordisk an interim injunction, preventing Indian companies Dr. Reddy’s Laboratories (DRL) and OneSource Specialty Pharma from selling or marketing semaglutide (the key ingredient in Ozempic/Wegovy) within India. However, they were allowed to manufacture and export to countries where Novo Nordisk’s patent does not apply. The order arose

Gauging the ‘Weight’ of the Matter: Here’s Your Latest Patent and Litigation Update on Semaglutide Read More »

https://upload.wikimedia.org/wikipedia/en/a/ae/Raanjhanaafilmposter.jpg

Raanjhanaa on the Big Screen (Again): Analysing the IPR Issues Triggered by An AI-Generated Ending

/ By / Copyright, Innovation

[A big thanks to Lokesh for his inputs in the post] The impending re-release of Raanjhanaa on August 1, 2025, with an AI-generated alternate ending, has reignited the long-standing tension between ownership and authorship. At a time when AI continues to be viewed with scepticism, especially within creative industries, this development adds another layer to the growing unease around artistic integrity. This isn’t the first time AI has stirred controversy in entertainment. I recall covering a similar flashpoint last year,

Raanjhanaa on the Big Screen (Again): Analysing the IPR Issues Triggered by An AI-Generated Ending Read More »

https://i.imgflip.com/a0vx9q.jpg

Keeping Up with The (GM) Crops: Comments and Caveats on the GEAC’s Punjab GM Crop Trials

/ By / Innovation

[A big thanks to Daanish Naithani for his inputs in the post.] If you were following the Genetically Modified (GM) crops dilemma last year but failed to keep up over the past year, don’t worry. Fortunately (and unfortunately, when seen in the broader scope), you haven’t really missed much. In July last year, as covered here on the blog, the Supreme Court (SC) delivered a split verdict on the commercial sale of Genetically Modified Mustard (GM Mustard) in India in

Keeping Up with The (GM) Crops: Comments and Caveats on the GEAC’s Punjab GM Crop Trials Read More »

https://www.google.com/url?sa=i&url=https%3A%2F%2Fabcnews.go.com%2FGMA%2FWellness%2Ffbi-issues-safety-warning-counterfeit-versions-weight-loss%2Fstory%3Fid%3D119792958&psig=AOvVaw0HjClYZU0507bVxSXAPbAC&ust=1750413713316000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCOi23K-d_Y0DFQAAAAAdAAAAABAE

Walking on ‘Thin’ Ice: DHC Domestically Injuncts Reddy’s from Selling Novo Nordisk’s Weightloss Drug

/ By / Patent

[A big thanks to Praharsh and Swaraj for their inputs on this post.] [Disclaimer: Long post ahead] A recent order (pdf) by the Delhi High Court (DHC) has drawn significant attention regarding the manufacture and availability of the diabetes management and weight-loss assistance drug semaglutide (sold as Wegovy and Ozempic). On 29 May 2025, the Single Bench (SB) comprising Justice Amit Bansal restrained Indian companies Dr. Reddy’s Laboratories (DRL) and OneSource Specialty Pharma Ltd (OSSPL) from selling semaglutide domestically in a

Walking on ‘Thin’ Ice: DHC Domestically Injuncts Reddy’s from Selling Novo Nordisk’s Weightloss Drug Read More »

https://i.imgflip.com/9uktko.jpg

Infringement or Not? DHC Refers Case to Larger Bench to Decide on Actions Against Registered Trademarks

/ By / Trademark

Can a registered trademark owner sue another one for infringement? If no, then how will the provision in Section 124 (5) of the Trademarks Act (“the Act”)  function, allowing courts to pass interim reliefs against a proprietor of a registered trademark? A Division Bench (“DB”) of the Delhi High Court (“DHC”) has recently encountered a Pandora’s box of a case, throwing up these important issues concerning trademark infringement cases. In Abros Sports International Pvt. Ltd. v. Ashish Bansal & Ors,

Infringement or Not? DHC Refers Case to Larger Bench to Decide on Actions Against Registered Trademarks Read More »

https://i.imgflip.com/9ojkje.jpg

[PART II] Personality Rights in Spotlight Once More!: Analysing The BomHC’s Karan Johar v.  India Pride Advisory Order 

/ By / Others

[A big thanks to Praharsh for his inputs on the post.] This is Part II of the two-part post on the recent Bombay High Court (BomHC) order in the case of Karan Johar v. India Pride Advisory Private Ltd. & Ors that has once again brought to the spotlight the debate of balancing the protection of celebrity’ personality rights and the freedom of expressions and parodical use. In Part I of the post (here), the BomHC’s decision and analysis of

[PART II] Personality Rights in Spotlight Once More!: Analysing The BomHC’s Karan Johar v.  India Pride Advisory Order  Read More »

https://assets-in.bmscdn.com/discovery-catalog/events/et00401267-qkelrdlyzd-landscape.jpg

[PART I] Personality Rights in Spotlight Once More!: Analysing The BomHC’s Karan Johar v.  India Pride Advisory Order

/ By / Others

[A big thanks to Praharsh for his inputs on the post.]  In Karan Johar v. India Pride Advisory Private Ltd. & Ors (pdf), Justice R.I. Chagla has delivered yet another drop in the bucket of multiple orders protecting personality rights that have been coming up in the past few years. The Bombay High Court order of 7th March 2025, making the interim injunction in favour of Karan Johar absolute, has added more fuel to the fire of the debate over

[PART I] Personality Rights in Spotlight Once More!: Analysing The BomHC’s Karan Johar v.  India Pride Advisory Order Read More »

Scroll to Top